Combination targeted therapy provides durable remission for patients with CLL
A combination of ibrutinib and venetoclax was found to provide lasting disease remission in patients with newly diagnosed chronic lymphocytic leukemia (CLL), according to researchers at The University of Texas MD Anderson ...
Jun 10, 2021
0
4